Evidence map›Paper›PMID 38778625›Full record

ReviewInflammatory bowel diseases2024

Challenges in IBD Research 2024: Novel Technologies.

Shalini Prasad, Raymond K Cross, Mary Beth Monroe, Michael T Dolinger, Rachel Motte, Sungmo Hong, Ryan W Stidham, Narendra Kumar, Deborah Levine, Anthony Larijani and 7 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammatory bowel diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Shalini PrasadDepartment of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.ORCID 0000-0002-2404-3801
Raymond K CrossDirector of the Inflammatory Bowel Disease Program, University of Maryland School of Medicine, Maryland, MD, USA.
Mary Beth MonroeDepartment of Biomedical and Chemical Engineering BioInspired Syracuse: Institute for Material and Living Systems, Syracuse University, Syracuse, NY, USA.
Michael T DolingerIcahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology, New York, NY, USA.ORCID 0000-0002-9023-4948
Rachel MotteTISSIUM, 74 Rue du Faubourg Saint-Antoine, Paris, France.
Sungmo HongDepartment of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
Ryan W StidhamDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Narendra KumarDepartment of Pharmaceutical Science, ILR-College of Pharmacy, Texas A&M University, TX, USA.
Deborah LevineDepartment of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
Anthony LarijaniDepartment of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
Ashley SimoneDepartment of Bioengineering, The University of Texas at Dallas, Richardson, TX, USA.
Karen A ChachuDepartment of Medicine, Division of Gastroenterology, Duke University School of Medicine, Durham, NC, USA.
Russell WyborskiMembers of the Crohn's & Colitis Foundation, New York, NY, USA.
Caren A HellerMembers of the Crohn's & Colitis Foundation, New York, NY, USA.
Alan C MossMembers of the Crohn's & Colitis Foundation, New York, NY, USA.
Nicole M J SchwerbrockMembers of the Crohn's & Colitis Foundation, New York, NY, USA.ORCID 0009-0001-8248-4963
Florin M SelaruDivision of Gastroenterology, Oncology and Biomedical Engineering, Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.

Funding

Automated Measurement of Bowel Damage Using Enterography Imaging to Predict Clinical Outcomes in Crohn’s Disease.R01DK124779 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STIDHAM, RYAN WILLIAM · 2020 to 2023
$2.1M
CCFNIDDK NIH HHS R01 DK124779
6 · The paper itself

Abstract

Novel technology is one of the five focus areas of the Challenges in Inflammatory Bowel Disease (IBD) Research 2024 document. Building off the Challenges in IBD Research 2019 document, the Foundation aims to provide a comprehensive overview of current gaps in IBD research and deliver actionable approaches to address them with a focus on how these gaps can lead to advancements in interception, remission, and restoration for these diseases. The document is the result of a multidisciplinary collaboration from scientists, clinicians, patients, and funders and represents a valuable resource for patient-centric research prioritization. Specifically, the Novel Technologies section focuses on addressing key research gaps to enable interception and improve remission rates in IBD. This includes testing predictions of disease onset and progression, developing novel technologies tailored to specific phenotypes, and facilitating collaborative translation of science into diagnostics, devices, and therapeutics. Proposed priority actions outlined in the document include real-time measurement of biological changes preceding disease onset, more effective quantification of fibrosis, exploration of technologies for local treatment of fistulas, and the development of drug delivery platforms for precise, location-restricted therapies. Additionally, there is a strong emphasis on fostering collaboration between various stakeholders to accelerate progress in IBD research and treatment. Addressing these research gaps necessitates the exploration and implementation of bio-engineered novel technologies spanning a spectrum from materials to systems. By harnessing innovative ideas and technologies, there's a collective effort to enhance patient care and outcomes for individuals affected by IBD.

Indexed as

Inflammatory Bowel DiseasesBiomedical ResearchHumansbioengineeringCrohn’s diseasefibrosisreal-time measurementtargeting inflammationulcerative colitis

Identifiers

PMID38778625
PMCPMC12102477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.